VJDementia Podcast

Synaptic function in Alzheimer’s disease

This podcast will provide an overview of the importance of synapses in Alzheimer's disease (AD) presented at the AD/PD 2022 and ARUK 2022 meetings. Discover the thoughts of leading authorities Afia Ali, PhD, UCL School of Pharmacy, University College London, London, UK; Makis Tzioras, PhD, The University of Edinburgh, Edinburgh, UK; and Thomas Südhof, MD, Stanford University School of Medicine, Stanford, CA – as they discuss the significance of synapses in AD.

Novel developments in biomarkers for FTD

New biomarkers are needed that are sensitive to subtle changes, to improve diagnosis and disease monitoring in frontotemporal dementia (FTD). Martina Bocchetta, PhD, University College London, London, UK; Annakaisa Haapasalo, PhD, University of Eastern Finland, Joensuu, Finland; and Adolfo Garcia, PhD, University of San Andrés, Buenos Aires, Argentina, discuss the development of novel biomarkers for FTD.

Therapeutic plasma exchange to slow cognitive decline in Alzheimer’s disease

Dementia specialists Mercè Boada, MD, PhD, Fundació ACE, International University of Catalonia, Barcelona, Spain; Javier Olazarán, MD, PhD, Gregorio Marañón Hospital, Madrid, Spain; and Miquel Lozano, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discuss the use of plasma exchange plus albumin replacement as an innovative treatment for Alzheimer´s disease, from rationale through to Phase III data and clinical implementation.

Recent advances in plasma biomarkers for Alzheimer’s disease

In today’s episode, Stephen Salloway, MD, MS, of Warren Alpert Medical School of Brown University, Providence, RI, Nicholas Ashton, PhD, of the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, Kira Trares, MSc, of the University of Heidelberg, Germany, and Joyce Van Arendonk, MSc, of the Erasmus MC University Medical Center, The Netherlands, talk on the latest advances in plasma biomarkers for Alzheimer’s disease, including recent studies and future perspectives.